ArticlePloS one2025
Future Sequon Finder - A novel approach for predicting future N-linked glycosylation sequon locations on viral surface proteins.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza viruses are known to evade host immune responses by shielding vulnerable surface protein epitopes via N-linked glycosylation. A program titled Future Sequon Finder was developed to predict the locations in which glycan binding sites are most likely to emerge in future influenza hemagglutinin proteins. The predictive modeling approach considers how closely sites in currently circulating strains resemble glycosylation sequons at the nucleic acid level, the surface accessibility of those sites, and the mutation frequency of amino acids at those sites that would need to change to form a glycosylation sequon. The efficacy of this model is tested using historic human H1N1 and H3N2 influenza strains along with swine H1N1 strains. Through this analysis, it is revealed that glycosylation addition events in influenza hemagglutinin proteins are typically the result of single nucleotide mutation events. It is also demonstrated that site-specific mutation frequency and surface accessibility are powerful predictors of which sites will become glycosylated in human influenza viruses when considered with the genetic composition of the sites in question. Having been designed to incorporate these factors, the program successfully predicted almost every historic sequon addition event (28/30 in human IFVs, 14/15 in swine IFVs). For human strains, it also ranked the correct near-sequons highly among falsely predicted sequons based on site-specific mutation frequency. After demonstrating the model's power with historical data, the program was used to predict future HA glycosylation sequon locations based on currently circulating human influenza viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.